## Note
nid: 1496034995094
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Dupilumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Dupilumab, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::3-HighYield-temporary
markdown: false

### Text
<div>
  <div>
    <b>Dupilumab</b> is a monoclonal antibody against the
    {{c1::<b>IL4</b>}} receptor <i>alpha</i> subunit
  </div>
</div>

### Extra
This allows it to block both the <b>IL-4 and</b> <b>IL-13</b>
receptors (both use the IL-4R alpha chain)
<div><img src="fig2.jpg"></div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_4.png"></a>
</div>

### Additional Resources


### One by one

